What your sad desk sandwich says about your working habits 
Boxers, briefs and bacterial vaginosis: how your underwear can affect your health 
Meta AI to Supercharge WhatsApp, Facebook, Instagram via Powerful Integration 
The Original Mouthful: McDonald's Australia Revives Legendary Big Mac Chant with a Tech Twist 
Why China’s economy has hit a wall 
Be wary of the ‘vibes’: positive investor sentiment doesn’t necessarily match the true value of stocks 
Huawei Unveils Pura 70 Series to Rival Apple's Dominance in China's Smartphone Arena 
Mister Donut and Gion Tsujiri Unite Once More for Kyoto-Inspired Donut Delights 
Google Fired Workers Protesting Over Cloud Contract Deal With Israel 
Sitting is bad for your health and exercise doesn’t seem to offset the harmful effects 
Sony Pictures, Apollo Global Reportedly In Talks to Jointly Bid for Paramount 
Personalized cancer treatments based on testing drugs quickly leads to faster treatment, better outcomes 
Digital trade protocol for Africa: why it matters, what’s in it and what’s still missing 
Online wellness content: 3 ways to tell evidence-based health information from pseudoscience 
SK Bioscience has applied for conditional approval for the use of SKY Covione, a COVID-19 vaccine, with the European Medicines Agency (EMA).
SKY Covione, developed jointly by the biotech affiliate of SK Group and the Institute for Protein Design (IPD) at the University of Washington, is a synthetic vaccine considered safer than those originating from bacterial cultures.
The Bill & Melinda Gates Foundation provided funding for the product development.
According to Phase 3 clinical studies, the vaccine is significantly more immunogenic than the control vaccination Vaxzeria from AstraZeneca, according to SK Bioscience.
Extensive research in Phase 1 therapeutic trials showed that SKY Covione also induced a potent immune response against BA.1, of the Omicron variant family, when provided with booster shots.
The SK affiliate anticipates that the product will have a competitive advantage in the international market, which requires a consistent and stable supply of vaccines in the upcoming months.
Once it is added to the World Health Organization (WHO) Emergency Use List, it will be distributed to the global market through the COVID-19 Vaccines Global Access (COVAX) project, a global program created to enable equal access to COVID-19 vaccines.
According to data from the Korea Customs Service, Korea imported $2.35 billion worth of vaccines last year, a seven-fold rise from $340 million the year before.
